<DOC>
	<DOC>NCT00423163</DOC>
	<brief_summary>To evaluate the therapeutic effectiveness of voriconazole + micafungin versus voriconazole alone as primary therapy for invasive aspergillosis.</brief_summary>
	<brief_title>A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis</brief_title>
	<detailed_description />
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Proven, probable or possible invasive aspergillosis Patient is 2 years of age or older The patient has been administered an antifungal agent (voriconazole, itraconazole, posaconazole, caspofungin, micafungin, anidulafungin, amphotericin B, or lipid formulation of amphotericin B) for &gt;7 days immediately prior to randomization for treatment of the Possible, Probable, or Proven invasive aspergillosis for which the patient is being enrolled. The patient has been treated with voriconazole for &gt; 7 days immediately prior to randomization</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Aspergillosis/blood</keyword>
	<keyword>micafungin</keyword>
	<keyword>voriconazole</keyword>
	<keyword>Aspergillus</keyword>
</DOC>